Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND GO2: RVT-1401 in Moderate to Severe Active Graves' Ophthalmopathy
2018-004676-35Phase 2Terminated
- Sponsor
- Immunovant, Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Graves' ophthalmopathy (TED) comparing RVT-1401 with Placebo (2 arms). Primary endpoint: Proptosis responder rate at week 13 (primary). Started May 2019; status: terminated.
02
Drugs
batoclimab
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2018-004676-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004676-35.